|
TW212792B
(cg-RX-API-DMAC7.html)
*
|
1991-09-13 |
1993-09-11 |
Shell Internat Res Schappej B V |
|
|
WO2004054977A1
(en)
|
2002-12-13 |
2004-07-01 |
Cytopia Pty Ltd |
Nicotinamide-based kinase inhibitors
|
|
US20090069300A1
(en)
*
|
2007-09-12 |
2009-03-12 |
Wyeth |
Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists
|
|
WO2012154760A1
(en)
*
|
2011-05-10 |
2012-11-15 |
Gilead Sciences, Inc. |
Fused heterocyclic compounds as sodium channel modulators
|
|
WO2013155223A1
(en)
|
2012-04-10 |
2013-10-17 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
|
WO2014160200A1
(en)
|
2013-03-13 |
2014-10-02 |
Dana-Farber Cancer Institute, Inc. |
Ras inhibitors and uses thereof
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
|
MX380928B
(es)
|
2013-10-10 |
2025-03-12 |
Araxes Pharma Llc |
Inhibidores de kras g12c.
|
|
US9862701B2
(en)
|
2014-09-25 |
2018-01-09 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
AU2016245864C1
(en)
*
|
2015-04-10 |
2021-09-09 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
|
WO2016176338A1
(en)
|
2015-04-30 |
2016-11-03 |
The Trustees Of Columbia University In The City Of New York |
Small molecule ras ligands
|
|
AU2016258192B2
(en)
|
2015-05-06 |
2021-07-29 |
Leidos Biomedical Research, Inc. |
K-Ras modulators
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
KR102932353B1
(ko)
|
2015-11-16 |
2026-02-27 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
JP2019529484A
(ja)
|
2016-09-29 |
2019-10-17 |
アラクセス ファーマ エルエルシー |
Kras g12c変異体タンパク質の阻害剤
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
AU2017378393B2
(en)
|
2016-12-14 |
2023-03-09 |
Bt Bidco, Inc. |
Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
|
|
EP3558979B1
(en)
|
2016-12-22 |
2021-02-17 |
Boehringer Ingelheim International GmbH |
Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
|
|
JOP20190186A1
(ar)
|
2017-02-02 |
2019-08-01 |
Astellas Pharma Inc |
مركب كينازولين
|
|
CA3056970A1
(en)
|
2017-03-21 |
2018-09-27 |
Bayer Pharma Aktiengesellschaft |
2-methyl-quinazolines
|
|
US11047054B2
(en)
|
2017-04-19 |
2021-06-29 |
California Institute Of Technology |
Oxygen evolution reaction catalysis
|
|
US11358940B2
(en)
*
|
2017-04-20 |
2022-06-14 |
The Regents Of The University Of California |
K-Ras modulators
|
|
WO2018206539A1
(en)
|
2017-05-11 |
2018-11-15 |
Astrazeneca Ab |
Heteroaryl compounds that inhibit g12c mutant ras proteins
|
|
UA127968C2
(uk)
|
2017-05-22 |
2024-02-28 |
Емджен Інк. |
Інгібітори g12c kras і способи їх застосування
|
|
TW201906832A
(zh)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
用於癌症治療之化合物及其使用方法
|
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
|
CN110869358A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
Kras的共价抑制剂
|
|
US10640504B2
(en)
|
2017-09-08 |
2020-05-05 |
Amgen Inc. |
Inhibitors of KRAS G12C and methods of using the same
|
|
CA3082579A1
(en)
|
2017-11-15 |
2019-05-23 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
EP3718514A4
(en)
|
2017-11-29 |
2021-07-28 |
Bridgestone Corporation |
RUBBER COMPOSITION FOR A PROSTHESIS FOOT SOLE AND PROSTHESIS FOOT SOLE
|
|
WO2019104505A1
(zh)
|
2017-11-29 |
2019-06-06 |
中车资阳机车有限公司 |
一种用于油--电混合动力机车车载动力电池的充电系统
|
|
PL3728254T3
(pl)
|
2017-12-21 |
2023-06-12 |
Boehringer Ingelheim International Gmbh |
Benzyloaminopodstawione pirydopirymidynony i pochodne jako inhibitory sos1
|
|
SG10202102462SA
(en)
|
2018-01-19 |
2021-04-29 |
Medshine Discovery Inc |
Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor
|
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
|
WO2019204442A1
(en)
|
2018-04-18 |
2019-10-24 |
Theras, Inc. |
K-ras modulators with a cyanoacrylamide moiety
|
|
TW202012371A
(zh)
|
2018-04-18 |
2020-04-01 |
美商德洛斯股份有限公司 |
具乙烯碸部分之k-ras調節劑
|
|
EP3781565A1
(en)
|
2018-04-18 |
2021-02-24 |
Bayer Pharma Aktiengesellschaft |
2-methyl-aza-quinazolines
|
|
MX2020010836A
(es)
|
2018-05-04 |
2021-01-08 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso.
|
|
EP3788053B1
(en)
|
2018-05-04 |
2024-07-10 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
WO2019217307A1
(en)
|
2018-05-07 |
2019-11-14 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
TW202012415A
(zh)
|
2018-05-08 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
|
WO2019217691A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
|
AU2019284472B2
(en)
|
2018-06-11 |
2024-05-30 |
Amgen Inc. |
KRAS G12C inhibitors for treating cancer
|
|
JP2021176820A
(ja)
|
2018-07-31 |
2021-11-11 |
アステラス製薬株式会社 |
キナゾリン化合物を有効成分とする医薬組成物
|
|
JP2021176819A
(ja)
|
2018-07-31 |
2021-11-11 |
アステラス製薬株式会社 |
キナゾリン化合物を有効成分とする医薬組成物
|
|
CN112119075B
(zh)
|
2018-08-16 |
2024-03-12 |
豪夫迈·罗氏有限公司 |
稠环化合物
|
|
ES2961253T3
(es)
|
2018-08-31 |
2024-03-11 |
Mirati Therapeutics Inc |
Inhibidores de KRas G12C
|
|
AR116604A1
(es)
*
|
2018-10-15 |
2021-05-26 |
Lilly Co Eli |
Inhibidores de kras g12c
|
|
WO2020097537A2
(en)
|
2018-11-09 |
2020-05-14 |
Genentech, Inc. |
Fused ring compounds
|
|
EP3887373A1
(en)
|
2018-11-29 |
2021-10-06 |
Araxes Pharma LLC |
Compounds and methods of use thereof for treatment of cancer
|
|
WO2020146613A1
(en)
|
2019-01-10 |
2020-07-16 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
WO2020180768A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
|
US20230096028A1
(en)
|
2019-03-01 |
2023-03-30 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
|
CN113874374B
(zh)
|
2019-05-24 |
2024-12-27 |
江苏恒瑞医药股份有限公司 |
氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
CN112300153B
(zh)
|
2019-07-26 |
2023-06-13 |
博瑞生物医药(苏州)股份有限公司 |
一种杂环化合物、药物组合物和用途
|
|
US20210040089A1
(en)
|
2019-08-07 |
2021-02-11 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitors
|
|
CN114615981B
(zh)
|
2019-08-29 |
2024-04-12 |
米拉蒂治疗股份有限公司 |
Kras g12d抑制剂
|
|
PH12022551102A1
(en)
|
2019-11-08 |
2023-11-20 |
Revolution Medicines Inc |
Bicyclic heteroaryl compounds and uses thereof
|
|
CR20220258A
(es)
|
2019-12-11 |
2022-07-03 |
Lilly Co Eli |
Inhibidores de kras g12c
|
|
PH12022551513A1
(en)
|
2019-12-20 |
2023-04-24 |
Mirati Therapeutics Inc |
Sos1 inhibitors
|
|
TW202144349A
(zh)
|
2020-04-30 |
2021-12-01 |
大陸商上海科州藥物研發有限公司 |
作為kras抑制劑的雜環化合物的製備及其應用方法
|
|
CA3191279A1
(en)
|
2020-08-28 |
2022-03-03 |
Yi Liu |
Heterocyclic compounds and uses thereof
|
|
CN114380827A
(zh)
|
2020-10-22 |
2022-04-22 |
贝达药业股份有限公司 |
Kras g12c抑制剂及其在医药上的应用
|
|
WO2022105859A1
(en)
|
2020-11-20 |
2022-05-27 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras g12d inhibitors
|
|
CN113999226B
(zh)
|
2020-12-22 |
2023-01-06 |
上海科州药物研发有限公司 |
作为kras抑制剂的杂环化合物的制备及其应用方法
|
|
WO2022135470A1
(zh)
|
2020-12-22 |
2022-06-30 |
上海科州药物研发有限公司 |
作为kras抑制剂的杂环化合物的制备及其应用方法
|
|
WO2022148422A1
(en)
|
2021-01-08 |
2022-07-14 |
Beigene, Ltd. |
Bridged compounds as kras g12d inhibitor and degrader and the use thereof
|
|
WO2022170999A1
(zh)
|
2021-02-09 |
2022-08-18 |
南京明德新药研发有限公司 |
吡啶[4,3-d]嘧啶类化合物
|
|
JP2024505594A
(ja)
|
2021-02-09 |
2024-02-06 |
メッドシャイン ディスカバリー インコーポレイテッド |
ピリミジン芳香環化合物
|
|
AU2022220678A1
(en)
|
2021-02-09 |
2023-09-21 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
MX2023008463A
(es)
|
2021-02-16 |
2023-12-07 |
Leidos Biomedical Res Inc |
Composiciones y métodos para la inhibición del gen del virus de sarcoma de rata kirsten (kras).
|
|
WO2022184178A1
(en)
|
2021-03-05 |
2022-09-09 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras g12d inhibitors
|
|
US20240239788A1
(en)
|
2021-04-16 |
2024-07-18 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras g12d mutant
|
|
CN115490709A
(zh)
|
2021-04-30 |
2022-12-20 |
四川海思科制药有限公司 |
一种krasg12d抑制剂及其在医药上的应用
|
|
US20240300980A1
(en)
|
2021-05-22 |
2024-09-12 |
Shanghai Kechow Pharma, Inc. |
Heterocyclic compounds as kras inhibitor, and preparation therefor and use thereof in treatment
|
|
CN117500799A
(zh)
|
2021-06-09 |
2024-02-02 |
伊莱利利公司 |
作为kras g12d抑制剂的取代的稠合吖嗪
|
|
WO2022258974A1
(en)
|
2021-06-10 |
2022-12-15 |
Redx Pharma Plc |
Quinazoline derivatives useful as ras inhibitiors
|
|
CA3221608A1
(en)
|
2021-06-14 |
2022-12-22 |
Kumquat Biosciences Inc. |
Fused heteroaryl compounds useful as anticancer agents
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
CN115611923A
(zh)
|
2021-07-12 |
2023-01-17 |
贝达药业股份有限公司 |
Kras g12d抑制剂及其在医药上的应用
|
|
CA3227138A1
(en)
|
2021-07-23 |
2023-01-26 |
Theras, Inc. |
Compositions and methods for inhibition of ras
|
|
EP4384522A1
(en)
|
2021-08-10 |
2024-06-19 |
Erasca, Inc. |
Selective kras inhibitors
|
|
WO2023020519A1
(en)
|
2021-08-18 |
2023-02-23 |
Jacobio Pharmaceuticals Co., Ltd. |
1, 4-oxazepane derivatives and uses thereof
|